Effect of tegoprazan on temporal variability of platelet reactivity in patients treated with clopidogrel after coronary stenting

1 7

Cited 0 times in

MeSH: Aged ; Aspirin ; Blood Platelets* / drug effects ; Blood Platelets* / metabolism ; Clopidogrel* / adverse effects ; Clopidogrel* / therapeutic use ; Coronary Artery Disease* / blood ; Coronary Artery Disease* / therapy ; Drug Interactions ; Drug Therapy, Combination ; Dual Anti-Platelet Therapy / adverse effects ; Female ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention* / adverse effects ; Percutaneous Coronary Intervention* / instrumentation ; Platelet Activation* / drug effects ; Platelet Aggregation Inhibitors* / adverse effects ; Platelet Aggregation Inhibitors* / therapeutic use ; Platelet Function Tests ; Proton Pump Inhibitors* / adverse effects ; Proton Pump Inhibitors* / therapeutic use ; Retrospective Studies ; Stents* ; Time Factors ; Treatment Outcome

Keywords: Blood platelets ; Clopidogrel ; Platelet function tests ; Potassium-competitive acid blocker ; Proton pump inhibitors

Abstract: Background/aims: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity.

Methods: Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays.

Results: Platelet reaction unit (PRU) values at 3 (157 ± 8 vs. 162 ± 6, p = 0.659), 6 (167 ± 9 vs. 158 ± 7, p = 0.370), and 12 months (155 ± 10 vs. 164 ± 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as ≥ 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503).

Conclusion: There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.